For HR+/HER2−/luminal B-like tumors, the use of CT is contingent on the expression of hormonal receptors (estrogen/progesterone), proliferative markers (Ki67 expression), tumor burden, genomically-assessed risk, and/or patient preference [1]. The gene discussed is NR4A1; the disease is neoplasm.